SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Two Novartis AG Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®